Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

Nabriva Soars on Agreement With Merck to Distribute Sivextro

DUBLIN, Ireland and KING OF PRUSSIA, Pa., July  15, 2020  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

Nabriva's Shares March Higher, Can It Continue?

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May  29, 2020  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management & Research Company, LLC, for the purchase and sale of (i) an aggregate of 41,445,373 ordinary shares and (ii) warrants to purchase up to an aggregate of 41,445,373 ordinary shares in a registered direct offering priced at-the-market under Nasdaq rules.  Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $0.91686.  The warrants have an exercise price of $0.792 per share, are exercisable on the issuance date and will expire on the two-year anniversary of the issuance date.

Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript

Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)

Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick

DUBLIN, Ireland, April  09, 2020  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for XENLETA™ (lefamulin) 150 mg injection. The new billing code, J0691 Injection, will become effective July 1, 2020 and will replace the C Code, C9054. Transitional pass-through status, previously granted in 2019, for outpatient payments ends December 31, 2022.

Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA

DUBLIN, Ireland, April  08, 2020  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, at 11:20a.m. ET.

Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session

Nabriva Therapeutics' (NBRV) CEO Ted Schroeder on Q4 2019 Results - Earnings Call Transcript

Will Nabriva Therapeutics Continue to Surge Higher?

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec.  20, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering of (i) an aggregate of 13,793,106 ordinary shares and (ii) warrants to purchase up to an aggregate of 13,793,106 ordinary shares.  Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $1.45.  The warrants have an exercise price of $1.90 per share, are initially exercisable six months following issuance (the “Initial Exercise Date”) and will expire on the 3-year anniversary of the Initial Exercise Date.

Nabriva Therapeutics Announces $20 Million Registered Direct Offering

Shares of Nabriva Therapeutics PLC NBRV, -3.37% soared 10.5% in premarket trading Friday, after the biotechnology company said it resubmitted its new drug application (NDA) for Contepo, its treatment for complicated urinary tract infections.

Nabriva's stock soars after resubmitting NDA for UTI treatment

-Nabriva anticipates a six-month review period by the Food and Drug Administration

Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

DUBLIN, Ireland, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 18,000 ordinary shares of Nabriva Therapeutics as inducements to 4 newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.

Nabriva Therapeutics  Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.

Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q3 2019 Results - Earnings Call Transcript

Athenex

Dynavax Technologies

Farfetch

SNDL Inc.

Investors want to know which stocks are set to take flight. We are talking about stocks with serious growth prospects here, or names that can more than double investors’ returns in the next year.

News for Nabriva Therapeutics Stock (NBRV)